Analysts expect Merck & Company, Inc. (NYSE:MRK) to announce sales of $10.45 billion for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Merck &’s earnings, with the highest sales estimate coming in at $10.52 billion and the lowest estimate coming in at $10.32 billion. Merck & posted sales of $10.54 billion during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.9%. The company is expected to announce its next earnings results before the market opens on Friday, October 27th.

According to Zacks, analysts expect that Merck & will report full year sales of $10.45 billion for the current fiscal year, with estimates ranging from $40.12 billion to $40.52 billion. For the next fiscal year, analysts expect that the company will post sales of $41.29 billion per share, with estimates ranging from $40.60 billion to $41.87 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Merck &.

Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.93 earnings per share.

Several equities analysts have issued reports on the stock. HSBC Holdings plc upgraded shares of Merck & from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 9th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. UBS AG increased their price objective on shares of Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and issued a $74.00 price objective on shares of Merck & in a research note on Tuesday, June 6th. Finally, Zacks Investment Research cut shares of Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $70.00.

Merck & (NYSE:MRK) opened at 65.13 on Monday. The stock has a 50 day moving average of $63.52 and a 200 day moving average of $63.68. The stock has a market cap of $177.63 billion, a P/E ratio of 35.26 and a beta of 0.81. Merck & has a 1-year low of $58.29 and a 1-year high of $66.80.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is currently 76.11%.

Institutional investors and hedge funds have recently made changes to their positions in the business. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Merck & by 133.4% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock valued at $9,165,000 after purchasing an additional 82,454 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its holdings in shares of Merck & by 41.9% in the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock valued at $19,028,000 after purchasing an additional 87,443 shares in the last quarter. Stevens Capital Management LP purchased a new position in shares of Merck & in the first quarter valued at $15,126,000. Klingenstein Fields & Co. LLC grew its holdings in shares of Merck & by 5.4% in the first quarter. Klingenstein Fields & Co. LLC now owns 446,450 shares of the company’s stock valued at $28,368,000 after purchasing an additional 22,958 shares in the last quarter. Finally, Bridges Investment Management Inc. grew its holdings in shares of Merck & by 18.0% in the second quarter. Bridges Investment Management Inc. now owns 46,436 shares of the company’s stock valued at $2,976,000 after purchasing an additional 7,070 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/25/10-45-billion-in-sales-expected-for-merck-company-inc-mrk-this-quarter.html.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Get a free copy of the Zacks research report on Merck & (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.